Cartalax vs kpv
Cartalax (C-tier) vs kpv (B-tier). mechanism, trials, claims vs data, dosing literature. side-by-side reference.
Cartalax — tier C
an identity-gated Ala-Glu-Asp tripeptide with cell and animal work plus one poorly reported, 29-person saline-controlled human example in an assignee patent, but no independent peer-reviewed replication or measured pharmacokinetic curve.
the exact AED tripeptide has a real chemical identity, preclinical signals, and one sparse assignee-patent human signal, but the consequential claims remain behind weak reporting, absent independent replication, and a product-identity gate.
29 people in patent Example 5 · half-life unknown; no measured concentration-time half-life · healing
kpv — tier B
tiny three-amino-acid peptide for inflammation. IBD, eczema, autoimmune. none of α-MSH's tanning or appetite side effects.
a three-amino-acid fragment of alpha-MSH. preserves the anti-inflammatory tail without the tanning, appetite, or arousal effects.
picomolar NF-kB inhibition · half-life short in plasma; stable in GI tract (unusual for a peptide, supports oral delivery) · healing
at a glance
reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.
